Patents by Inventor Melissa Lasaro

Melissa Lasaro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR INHIBITING COMPLEMENT COMPONENT 3 EXPRESSION
    Publication number: 20250002908
    Abstract: Described herein are oligonucleotides (e.g., RNAi oligonucleotides) containing a sense and antisense strands for targeting complement component 3 (C3) mRNA. The RNAi oligonucleotide may be used to inhibit C3 expression, levels, and/or activity in a cell. Also, described herein are methods for using an oligonucleotide (e.g., an RNAi oligonucleotide) for the prophylaxis or treatment of a disease, disorder, or condition mediated by complement pathway activation or dysregulation.
    Type: Application
    Filed: April 20, 2022
    Publication date: January 2, 2025
    Applicant: AstraZeneca Ireland Limited
    Inventors: Melissa Lasaro, Susan Faas McKnight, Henryk T. Dudek, Jihye Park, Bob Dale Brown, Chengjung Lai, SungKwon Kim
  • MODIFIED mRNA ENCODING A URIDINE DIPHOPSPHATE GLUCURONOSYL TRANSFERASE AND USES THEREOF
    Publication number: 20190307857
    Abstract: The invention relates to methods and compositions for treating a UDP glucuronosyltransferase family 1 deficiency based on mRNA therapy.
    Type: Application
    Filed: December 9, 2016
    Publication date: October 10, 2019
    Applicant: ModernaTX, Inc.
    Inventors: Melissa Lasaro, David Osterman, Haren Vasavada, Christian Cobaugh